PSDV - pSivida Limited Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PSDV - pSivida Limited

PSDV 1.220

+14.0%

Mar 29 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John McCarthy who wrote (182)	9/27/2009 3:09:19 PM
From: John McCarthy	Read Replies (1) of 421

P#6 - pSivida Ltd. Reports Operating Results (10-K) gurufocus.com gurufocus.com SEVERE EDIT - SELECTION - REARRANGEMENT BrachySil for Pancreatic Cancer. Our BrachySil product candidate is designed to treat pancreatic cancer. BrachySil is injected through a needle directly to the tumor site in an in-office procedure. BrachySil delivers P32, a beta-emitting radioactive isotope that has been shown to shrink tumors. Because this radiation is also harmful to healthy tissue, use of BrachySil is designed to reduce radiation dispersed beyond the area of the tumor, as compared to existing P32-based products that allow the isotope to dissolve, disperse throughout the body and harm healthy tissue in other parts of the body. We believe BrachySil has a number of potentially advantageous attributes: • Short range. P32 isotope has a short active range resulting in less damage to healthy tissue; • Range of tumors. Fine gauge needle delivery allows potential application to a range of solid tumors; • Direct delivery. Injection via fine gauge needle minimizes side effects and tissue trauma; • Distribution. P32 half-life of 14 days allows more logistically convenient distribution to hospitals and application in the patient; • Immobilization. P32 particles are generally localized in the tumor, significantly reducing risk of leakage or systemic side effects.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next